1H-异吲哚-1,3(2H)-二酮,5-氨基-2-[2,6-二(1-甲基乙基)苯基]- | 100823-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 1H-异吲哚-1,3(2H)-二酮,5-氨基-2-[2,6-二(1-甲基乙基)苯基]-
• 英文名称: 5APP-33
• 英文别名: 2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione；TC11；(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione；1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-；5-amino-2-[2,6-di(propan-2-yl)phenyl]isoindole-1,3-dione
• CAS: 100823-03-8
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.407
• InChiKey: NRPIRIUWEKTNGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙酰氯 、 1H-异吲哚-1,3(2H)-二酮,5-氨基-2-[2,6-二(1-甲基乙基)苯基]- 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-[2-[2,6-di(propan-2-yl)phenyl]-1,3-dioxoisoindol-5-yl]acetamide
  参考文献：
  名称：

  Inhibitors of NF-κB derived from thalidomide

  摘要：

  A series of compounds originally derived from thalidomide were synthesized and evaluated. The most potent compounds in this series, 5HPP-33 and compound 20, inhibited NF-kappaB activation in HeLa cells. Preliminary study indicated that the mechanism of inhibition of NF-kappaB activation is through inhibition of its translocation from the cytoplasm to the nucleus.

  DOI：

  10.1016/j.bmcl.2007.01.088
• 作为产物：
  描述：

  1H-异吲哚-1,3(2H)-二酮,2-[2,6-二(1-甲基乙基)苯基]-5-硝基- 在 palladium on activated charcoal 氢气 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 1H-异吲哚-1,3(2H)-二酮,5-氨基-2-[2,6-二(1-甲基乙基)苯基]-
  参考文献：
  名称：

  THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES

  摘要：

  本文描述了具有一般结构的沙利度胺类似化合物。其中，R1从羟基、氢和氨基组成的一组中选择。同时还描述了一种治疗血管异常的方法，例如新生血管形成和血管渗漏。将含有沙利度胺类似化合物的治疗有效量的组合物给患者进行治疗。该组合物还可以包括溶解剂、惰性填充剂、稀释剂、辅料或调味剂等药剂。

  公开号：

  US20080306134A1

文献信息

• THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES
  申请人：Chen Danyang

  公开号：US20080306134A1

  公开（公告）日：2008-12-11

  Thalidomide analog compounds having a general structure are described. R 1 is selected from a group comprising of hydroxy, hydrogen, and amino. Also described is a method for treating vascular abnormalities, such as neovascularization and vascular leakage. A therapeutically effective amount of a composition containing the thalidomide analog compound is administered to a patient. The composition may further include agents, such as solubilizing agents, inert fillers, diluents, excipients, or flavoring agents.

  本文描述了具有一般结构的沙利度胺类似化合物。其中，R1从羟基、氢和氨基组成的一组中选择。同时还描述了一种治疗血管异常的方法，例如新生血管形成和血管渗漏。将含有沙利度胺类似化合物的治疗有效量的组合物给患者进行治疗。该组合物还可以包括溶解剂、惰性填充剂、稀释剂、辅料或调味剂等药剂。
• MODIFIED PHENYLPHTHALIMIDE AND PHARMACEUTICAL COMPOSITION HAVING SAME AS ACTIVE INGREDIENT
  申请人：Keio University

  公开号：EP3530652A1

  公开（公告）日：2019-08-28

  A phenylphthalimide derivative represented by the following general formula is provided as a phenylphthalimide derivative useful against various cancers including multiple myeloma, wherein R1 is a group containing PEG or a hydroxy C1-5 alkoxy group binding to position 4 or position 5, R2 is an amino group at position 6, and R3 and R4 are each independently a hydrogen atom, an alkyl group, an aryl group, an aralkyl group, or an aryloxy group.

  由以下通式代表的苯基邻苯二甲酰亚胺衍生物可作为一种苯基邻苯二甲酰亚胺衍生物用于抗击包括多发性骨髓瘤在内的各种癌症、 其中，R1 是含有 PEG 的基团或与位置 4 或位置 5 结合的羟基 C1-5 烷氧基，R2 是位于位置 6 的氨基，R3 和 R4 各自独立地为氢原子、烷基、芳基、芳烷基或芳氧基。
• PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA
  申请人：Ionescu Dumitru

  公开号：US20100247659A1

  公开（公告）日：2010-09-30

  Novel methods are provided to prevent blindness associated with diabetic macular edema by administration of a phenylphthalimide analog. Additionally, sustainability of the effect of administration of the phenylphthalimide analog is improved via encapsulation with poly(lactic-co-glycolic acid) nanoparticles. Finally, a novel method for synthesizing (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione is disclosed.
• [EN] THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES<br/>[FR] ANALOGUES DE LA THALIDOMIDE DESTINÉS AU TRAITEMENT D'ANOMALIES VASCULAIRES
  申请人：CHARLESSON LLC

  公开号：WO2008154353A1

  公开（公告）日：2008-12-18

  [EN] Thalidomide analog compounds having a general structure (I) are described. R1 is selected from a group comprising of hydroxy, hydrogen, and amine. Also described is a method for treating vascular abnormalities, such as neovascularization and vascular leakage. A therapeutically effective amount of a composition containing the thalidomide analog compound is administered to a patient. The composition may further include agents, such as solubilizing agents, inert fillers, diluents, excipients, or flavoring agents.
  [FR] La présente invention concerne des composés analogues de la thalidomide de structure générale (I). R1 est choisi dans un groupe comprenant un groupe hydroxy, un atome d'hydrogène et un groupe amine. L'invention a également pour objet un procédé de traitement d'anomalies vasculaires, telles qu'une néovascularisation et une fuite vasculaire. Une quantité efficace sur le plan thérapeutique d'une composition renfermant le composé analogue de la thalidomide est administrée à un patient. La composition peut en outre renfermer des agents, tels que des agents de solubilisation, des agents de charge inertes, des diluants, des excipients ou des agents aromatisants.
• Inhibitors of NF-κB derived from thalidomide
  作者：Esperanza J. Carcache de-Blanco、Bulbul Pandit、Zhigen Hu、Jiandong Shi、Andrew Lewis、Pui-Kai Li

  DOI：10.1016/j.bmcl.2007.01.088

  日期：2007.11

  A series of compounds originally derived from thalidomide were synthesized and evaluated. The most potent compounds in this series, 5HPP-33 and compound 20, inhibited NF-kappaB activation in HeLa cells. Preliminary study indicated that the mechanism of inhibition of NF-kappaB activation is through inhibition of its translocation from the cytoplasm to the nucleus.